Artificial Intelligence
AI in Pathology Market worth $49 million | MarketsandMarkets
CHICAGO, July 14, 2023 /PRNewswire/ — In the near future, the AI in pathology industry is poised to revolutionize the field of diagnostics and patient care. Advancements in machine learning and computer vision technologies will enable AI algorithms to analyze pathology images with unprecedented accuracy and efficiency. Pathologists will benefit from AI-powered decision support systems that provide real-time insights, assist in complex diagnoses, and offer personalized treatment recommendations. With the ability to process vast amounts of data, AI algorithms will enhance the speed and precision of pathology workflows, leading to quicker and more accurate diagnoses. Moreover, predictive analytics capabilities will enable pathologists to anticipate disease progression and treatment outcomes, facilitating tailored interventions and improving patient outcomes. As AI continues to evolve, the integration of this technology into pathology practice will transform the way diseases are detected, diagnosed, and managed, ultimately revolutionizing healthcare delivery on a global scale.
AI in Pathology Market in terms of revenue was estimated to be worth $24 million in 2023 and is poised to reach $49 million by 2028, growing at a CAGR of 15.6% from 2023 to 2028 according to a new report by MarketsandMarkets™. Factors such as the growing digitalization of pathology, an increasing number of misdiagnosed cases and increasing infusion of AI in pathology to enhance lab efficiency are aiding the growth of this market. However, interoperability & transparency issues, the high setup and operational costs, and data privacy concerns in AI in the pathology market are expected to restrain market growth to a certain extent.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=86647266
Browse in-depth TOC on “AI in Pathology Market”248 – Tables48 – Figures265 – Pages
AI in Pathology Market Scope:
Report Coverage
Details
Market Revenue in 2023
$24 million
Estimated Value by 2028
$49 million
Growth Rate
Poised to grow at a CAGR of 15.6%
Market Size Available for
2021–2028
Forecast Period
2023–2028
Forecast Units
Value (USD Million)
Report Coverage
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered
Component, Neural Network, Application, End user
Geographies Covered
North America, Europe, Asia Pacific, Latin America and Middle East and Africa
Report Highlights
Updated financial information / product portfolio of players
Key Market Opportunities
Shortage of skilled pathologists
Key Market Drivers
Technology advancements in deep learning have enabled a synergy with artificial intelligence (AI) in pathology space
Software segment accounted for the largest share of the AI in pathology market, By component.
Based on component, the software segment accounted for the largest share of the global AI in pathology market in 2022. The large share of this segment can be attributed to pathologists’ high adoption of AI-based software due to factors such as high adaptability and interoperability and automation of various tasks in pathology, such as image analysis, data extraction, and report generation. These driving factors are shaping the adoption and development of AI-based software for pathology, offering significant potential for advancements in disease detection, diagnosis, and treatment planning. For instance, in December 2021, F. Hoffmann-La Roche Ltd. (Switzerland) launched its artificial intelligence (AI)-based digital pathology software to help pathologists evaluate breast cancer markers such as Ki-67, ER, and PR.
The drug discovery segment is expected to witness the highest growth rate in the AI in pathology market by application.
Based on application, the AI in pathology market is segmented into drug discovery, disease diagnosis and prognosis, clinical workflow, and training & education. The drug discovery segment is estimated to grow at the highest CAGR, during the forecast period. The growth in high throughput screening and imaging, increasing use of AI that is benefitting toxicology testing for illicit drugs, rising pharmaceutical & biotechnology R&D expenditure, and the ability of AI in pathology to accelerate the development of new therapeutics, improve diagnostic accuracy, and enhance personalized medicine approaches are the major factors responsible for the large share and high growth rate of the drug discovery application segment.
North America dominated the AI in pathology market in 2022.
The global market has been segmented based on region: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the AI in pathology market in 2022, followed by Europe and Asia Pacific. This market is also projected to grow at the highest CAGR. The large share and high growth rate of North America can be attributed to the increasing research funding and government initiatives for promoting precision medicine in the US, this region has always been at the forefront of implementing advanced technologies and integrated AI systems within the pathology labs, factors such as increasing need to enhance efficiency of labs, growing cases of misdiagnoses, rise in use of telepathology with AI advancements have also supported the growth of this market in North America.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=86647266
AI in Pathology Market Dynamics:
Drivers:
Technology advancements in deep learning have enabled a synergy with artificial intelligence (AI) in pathology spaceRestraints:
High cost of digital pathology systemsOpportunities:
Shortage of skilled pathologistsChallenges:
Lack of sufficient data to train the AI algorithmsKey Market Players:
The key players functioning in the AI in pathology market include Koninklijke Philips N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (US), Akoya Biosciences, Inc. (US), Aiforia Technologies Plc (Finland), Indica Labs Inc. (US), OptraScan (US), Ibex Medical Analytics Ltd. (Israel), Mindpeak GmbH (Germany), Tribun Health (France), Techcyte, Inc. (US), Deep Bio Inc. (Korea), Lumea Inc. (US), Visiopharm (Denmark), aetherAI (Taiwan), Aiosyn (Netherlands), Paige AI, Inc. (US), Proscia Inc. (US), PathAI, Inc. (US), Tempus Labs, Inc. (US), Konfoong Biotech International Co., Ltd. (China), DoMore Diagnostics AS (Norway), Verily Life Sciences, LLC (US), deepPath (US), and 4D Path Inc (US).
Recent Developments:
In April 2023, Indica Labs Inc. (US) signed an agreement with Lunit Inc. (South Korea). The agreement helped to provide a fully interoperable solution between Indica Labs’ HALO AP image management software platform and Lunit’s suite of AI pathology products.In March 2022, Ibex Medical Analytics Ltd. (Isarel) had partnered with Dedalus Group (Italy). Through this partnership, the company aimed to bring the power of artificial intelligence to digital pathology.In January 2022, Aiforia Technologies Plc (Finland) collaborated with Mayo Clinic (US). Under this collaboration, AI-powered pathology research support architecture was established at the Mayo Clinic to enable faster results and scalable studies in translational research.In December 2021, F. Hoffmann-La Roche Ltd. (Switzerland) launched its artificial intelligence (AI)-based digital pathology algorithms to help pathologists evaluate breast cancer markers such as Ki-67, ER, and PR.Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=86647266
AI in Pathology Market Advantages:
Improved Accuracy: AI algorithms can analyze large volumes of medical data with high precision and accuracy. They can detect subtle patterns, anomalies, and features in pathology images that might be difficult for human pathologists to identify. This leads to improved diagnostic accuracy and reduces the chances of errors.Enhanced Efficiency: AI algorithms can process pathology images at a much faster rate than humans. They can analyze and interpret large volumes of data in a fraction of the time it would take a human pathologist. This increased efficiency allows for quicker turnaround times in diagnoses, enabling faster patient treatment and management.Standardization of Diagnoses: Pathology diagnoses can sometimes be subjective, as different pathologists may interpret images differently. AI algorithms can help standardize diagnoses by providing consistent and objective assessments. This can lead to more uniform and reliable diagnoses, reducing inter-observer variability.Augmented Decision Support: AI algorithms can act as decision support tools for pathologists. They can provide relevant information, suggestions, and recommendations based on their analysis of pathology images. This assists pathologists in making more informed decisions and can help improve patient outcomes.Predictive Analytics: AI algorithms can analyze pathology data over time, identify patterns, and make predictions about disease progression, treatment response, and patient outcomes. This predictive analytics capability can aid in personalized medicine, allowing for tailored treatment plans and interventions.Education and Training: AI algorithms can be used as educational tools for pathologists in training. They can provide case examples, highlight important features, and offer guidance during the learning process. This can help improve the knowledge and skills of pathologists, especially in challenging or rare cases.Cost Reduction: By increasing efficiency and accuracy, AI in pathology has the potential to reduce healthcare costs. Faster diagnoses and optimized treatment plans can lead to better resource utilization and more effective allocation of healthcare resources.Related Reports:
High Throughput Screening Market – Global Forecasts to 2028
CRISPR Technology Market – Global Forecasts to 2028
ATP Assays Market – Global Forecasts to 2028
Cell-based assays Market – Global Forecasts to 2028
Digital Pathology Market – Global Forecasts to 2028
About MarketsandMarkets™:
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:Mr. Aashish MehraMarketsandMarkets™ INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: sales@marketsandmarkets.comResearch Insight: https://www.marketsandmarkets.com/ResearchInsight/ai-in-pathology-market.aspVisit Our Website: https://www.marketsandmarkets.com/Content Source: https://www.marketsandmarkets.com/PressReleases/ai-in-pathology.asp
Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/ai-in-pathology-market-worth-49-million–marketsandmarkets-301877366.html